Philip J. Vickers

5.3k citations

36 papers · 3.8k indexed · 2 hit papers · h-index 24

Pharmacology top 0.5%
Molecular Biology top 5%
Physiology top 2%
Genetics top 2%
Immunology top 5%

Co-authors: Jilly F. Evans Joseph A. Mancini Gary P. O’Neill Stacia Kargman John W. Gillard S Jothy Douglas K. Miller Richard A. F. Dixon
Topics: Asthma and respiratory diseases (15 papers)Estrogen and related hormone effects (11 papers)Inflammatory mediators and NSAID effects (9 papers)
Cited by: Pharmacology Biochemistry Physiology
Journals: Nature Proceedings of the National Academy of Sciences Journal of Biological Chemistry
Partner nations: Canada United States Germany

In The Last Decade

Philip J. Vickers

36 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer.

1995 723 citations Stacia Kargman, Gary P. O’Neill et al. PubMed profile →
Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis

1990 622 citations Richard A. F. Dixon, Ronald E. Diehl et al. Nature profile →

Peers

Countries citing papers authored by Philip J. Vickers

Since Specialization

Citations

This map shows the geographic impact of Philip J. Vickers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip J. Vickers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip J. Vickers more than expected).

Fields of papers citing papers by Philip J. Vickers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip J. Vickers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip J. Vickers. The network helps show where Philip J. Vickers may publish in the future.

Co-authorship network of co-authors of Philip J. Vickers

This figure shows the co-authorship network connecting the top 25 collaborators of Philip J. Vickers. A scholar is included among the top collaborators of Philip J. Vickers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip J. Vickers. Philip J. Vickers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Effect of 5-Lipoxygenase-Activating Protein (Flap) on Substrate Utilization by 5-Lipoxygenase 1997 ·Advances in experimental medicine and biology ·Philip J. Vickers,Carmela DeLuca,Elizabeth Wong,Mark Abramovitz	2
2	Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells 1997 ·Inflammation Research ·Elizabeth Wong,Carmela DeLuca,(unknown),S. Charleson,Wanda Cromlish,D. Denis,Stacia Kargman,Brian P. Kennedy,Marc Ouellet,Kathryn Skorey,Gary P. O’Neill,Philip J. Vickers,Denis Riendeau	34
3	5-Lipoxygenase-activating protein (FLAP) 1995 ·PubMed ·Philip J. Vickers	54
4	Arginine 120 of Prostaglandin G/H Synthase-1 Is Required for the Inhibition by Nonsteroidal Anti-inflammatory Drugs Containing a Carboxylic Acid Moiety 1995 ·Journal of Biological Chemistry ·Joseph A. Mancini,Denis Riendeau,Jean‐Pierre Falgueyret,Philip J. Vickers,Gary P. O’Neill	118
5	Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer.breakdown → 1995 ·PubMed ·Stacia Kargman,Gary P. O’Neill,Philip J. Vickers,Jilly F. Evans,Joseph A. Mancini,S Jothy	723
6	The binding of leukotriene biosynthesis inhibitors to site-directed mutants of human 5-lipoxygenase-activating protein 1994 ·Life Sciences ·Joseph A. Mancini,Marc G. Coppolino,(unknown),S. Charleson,Philip J. Vickers	13
7	Structural requirements for the binding of fatty acids to 5-lipoxygenase-activating protein 1994 ·European Journal of Pharmacology Molecular Pharmacology ·S. Charleson,Jilly F. Evans,Serge Léger,Hélène Perrier,Petpiboon Prasit,Zhaoyin Wang,Philip J. Vickers	22
8	Mutation of serine‐516 in human prostaglandin G/H synthase‐2 to methionine or aspirin acetylation of this residue stimulates 15‐R‐HETE synthesis 1994 ·FEBS Letters ·Joseph A. Mancini,Gary P. O’Neill,Christopher I. Bayly,Philip J. Vickers	73
9	5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. 1993 ·The Journal of Experimental Medicine ·John Woods,Jilly F. Evans,Diane Ethier,S Scott,Philip J. Vickers,(unknown),Jeffrey A. Heibein,S. Charleson,Irwin Singer	341
10	5‐lipoxygenase‐activating protein is an arachidonate binding protein 1993 ·FEBS Letters ·Joseph A. Mancini,Mark Abramovitz,Martha E. Cox,Elizabeth Wong,S. Charleson,Hélène Perrier,Zhaoyin Wang,(unknown),Philip J. Vickers	179
11	5‐Lipoxygenase‐activating protein stimulates the utilization of arachidonic acid by 5‐lipoxygenase 1993 ·European Journal of Biochemistry ·Mark Abramovitz,Elizabeth Wong,Martha E. Cox,Christopher D. Richardson,Chun Li,Philip J. Vickers	173
12	5-Lipoxygenase activity in the human pancreas. 1993 ·PubMed ·Joseph A. Mancini,Changlin Li,Philip J. Vickers	8
13	Leukotriene generation and metabolism in dogs: inhibition of biosynthesis by MK-0591. 1993 ·Journal of Pharmacology and Experimental Therapeutics ·Philip Tagari,Andreas Becker,Christine Brideau,Richard Frenette,(unknown),E Thomas,Philip J. Vickers,A. W. Ford‐Hutchinson	12
14	5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors. 1992 ·Molecular Pharmacology ·Joseph A. Mancini,Petpiboon Prasit,Marc G. Coppolino,(unknown),Serge Léger,Jilly F. Evans,John W. Gillard,Philip J. Vickers	31
15	Cross-species comparison of 5-lipoxygenase-activating protein. 1992 ·Molecular Pharmacology ·Philip J. Vickers,Gary P. O’Neill,Joseph A. Mancini,S. Charleson,Mark Abramovitz	12
16	Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition. 1992 ·Molecular Pharmacology ·S. Charleson,Petpiboon Prasit,Serge Léger,John W. Gillard,Philip J. Vickers,Joseph A. Mancini,(unknown),Jocelyne Guay,A. W. Ford‐Hutchinson,Jilly F. Evans	32
17	Identification and isolation of a membrane protein necessary for leukotriene production 1990 ·Nature ·Douglas K. Miller,John W. Gillard,Philip J. Vickers,Sharon Sadowski,Claire Leveillé,Joseph A. Mancini,(unknown),Richard A. F. Dixon,Anthony W. Ford‐Hutchinson,Réjean Fortin,(unknown),J A Rodkey,(unknown),Carol A. Rouzer,Irving S. Sigal,Catherine D. Strader,Jilly F. Evans	382
18	Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesisbreakdown → 1990 ·Nature ·Richard A. F. Dixon,Ronald E. Diehl,Evan E. Opas,Elaine Rands,Philip J. Vickers,Jilly F. Evans,John W. Gillard,Douglas K. Miller	622
19	A Multidrug-Resistant MCF-7 Human Breast Cancer Cell Line Which Exhibits Cross-Resistance to Antiestrogens and Hormone-Independent Tumor Growthin Vivo 1988 ·Molecular Endocrinology ·Philip J. Vickers,(unknown),Robert Shoemaker,Kenneth H. Cowan	137
20	Activation of folylpolyglutamate synthetase by pteroic acid 1985 ·Canadian Journal of Biochemistry and Cell Biology ·Philip J. Vickers,(unknown),Zdenek B. Pristupa,K. G. Scrimgeour	4

About Philip J. Vickers

Philip J. Vickers is a scholar working on Pharmacology, Physiology and Clinical Biochemistry, having authored 36 papers that have together received 3.8k indexed citations. Recurring topics across this work include Asthma and respiratory diseases (15 papers), Estrogen and related hormone effects (11 papers) and Inflammatory mediators and NSAID effects (9 papers). The work is most often cited by research in Pharmacology (1.5k citations), Biochemistry (531 citations) and Physiology (942 citations). Philip J. Vickers has collaborated with scholars based in Canada, United States and Germany. Frequent co-authors include Jilly F. Evans, Joseph A. Mancini, Gary P. O’Neill, Stacia Kargman, John W. Gillard, S Jothy, Douglas K. Miller, Richard A. F. Dixon, S. Charleson and Ronald E. Diehl. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact